Anti-Podocalyxin Monoclonal Antibody 47-mG2a Detects Lung Cancers by Immunohistochemistry

Shinji Yamada, Shunsuke Itai, Mika K. Kaneko, Yukinari Kato

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Lung cancer is one of the leading causes of cancer-related deaths in the world. Regardless of the advances in lung cancer treatments, the prognosis is still poor. Podocalyxin (PODXL) is a highly glycosylated type I transmembrane protein that is expressed in normal tissues, including the heart, pancreas, and breast. It is also found and used as a diagnostic marker in many cancers, such as renal, brain, breast, oral, and lung cancers. We previously developed specific and sensitive anti-PODXL monoclonal antibodies, PcMab-47 (mouse IgG1, kappa) and its mouse IgG2a-type (47-mG2a), both of which were suitable for immunohistochemical analyses of oral cancers. In this study, we investigated the utility of PcMab-47 and 47-mG2a for the immunohistochemical analyses of lung cancers. PcMab-47 stained 51/70 (72.9%) cases of lung cancer, whereas 47-mG2a stained 59/70 (84.3%) cases, indicating that the latter antibody is more sensitive and is useful for detecting PODXL in lung cancers.

Original languageEnglish
Pages (from-to)91-94
Number of pages4
JournalMonoclonal Antibodies in Immunodiagnosis and Immunotherapy
Issue number2
Publication statusPublished - 2018 Apr


  • Lung cancer
  • Monoclonal antibody
  • Podocalyxin


Dive into the research topics of 'Anti-Podocalyxin Monoclonal Antibody 47-mG2a Detects Lung Cancers by Immunohistochemistry'. Together they form a unique fingerprint.

Cite this